Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment

BMC Pediatrics

Stephen M Arpadi³  Elaine J Abrams³  Ashraf Coovadia¹  Lubbe Wiesner⁵  Sandra Meredith⁵  Helen McIlleron⁴  Leigh Martens¹  Renate Strehlau¹  Louise Kuhn²  Stephanie Shiau² 

[1] Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, University of the Witwatersrand, Johannesburg, South Africa;Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY USA;Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY USA;Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa;Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa

关键词: Pharmacokinetics;    Antiretroviral treatment outcomes;    Sex differences;    Children;    HIV;   

Others  :  1139025
DOI  :  10.1186/1471-2431-14-39

 received in 2013-10-16, accepted in 2014-02-06,  发布年份 2014

【 摘 要 】

Background

While studies of HIV-infected adults on antiretroviral treatment (ART) report no sex differences in immune recovery and virologic response but more ART-associated complications in women, sex differences in disease progression and response to ART among children have not been well assessed. The objective of this study was to evaluate for sex differences in response to ART in South African HIV-infected children who were randomized to continue ritonavir-boosted lopinavir (LPV/r)-based ART or switch to nevirapine-based ART.

Methods

ART outcomes in HIV-infected boys and girls in Johannesburg, South Africa from 2005–2010 were compared. Children initiated ritonavir-boosted lopinavir (LPV/r)-based ART before 24 months of age and were randomized to remain on LPV/r or switch to nevirapine-based ART after achieving viral suppression. Children were followed for 76 weeks post-randomization and then long-term follow up continued for a minimum of 99 weeks and maximum of 245 weeks after randomization. Viral load, CD4 count, lipids, anthropometrics, drug concentrations, and adherence were measured at regular intervals. Outcomes were compared between sexes within treatment strata.

Results

A total of 323 children (median age 8.8 months, IQR 5.1-13.5), including 168 boys and 155 girls, initiated LPV/r-based ART and 195 children were randomized. No sex differences in risk of virological failure (confirmed viral load >1000 copies/mL) by 156 weeks post-randomization were observed within either treatment group. Girls switched to nevirapine had more robust CD4 count improvement relative to boys in this group through 112 weeks post-randomization. In addition, girls remaining on LPV/r had higher plasma concentrations of ritonavir than boys during post-randomization visits. After a mean of 3.4 years post-randomization, girls remaining on LPV/r also had a higher total cholesterol:HDL ratio and lower mean HDL than boys on LPV/r.

Conclusions

Sex differences are noted in treated HIV-infected children even at a young age, and appear to depend on treatment regimen. Future studies are warranted to determine biological mechanisms and clinical significance of these differences.

Trial registration

ClinicalTrials.gov Identifier: NCT00117728

【 授权许可】

   
2014 Shiau et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC: Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001, 344(10):720-725.
• [2]Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, Quinn TC, Vlahov D: Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998, 352(9139):1510-1514.
• [3]Soon GG, Min M, Struble KA, Chan-Tack KM, Hammerstrom T, Qi K, Zhou S, Bhore R, Murray JS, Birnkrant DB: Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000–2008). AIDS Patient Care STDS 2012, 26(8):444-453.
• [4]Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, Colebunders R, Chiesi A, Lungren JD, Phillips AN: Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003, 32(4):452-461.
• [5]Ofotokun I, Pomeroy C: Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 2003, 11(2):55-59.
• [6]Bersoff-Matcha SJ, Miller WC, Aberg JA, van der Horst C, Hamrick HJ Jr, Powderly WG, Mundy LM: Sex differences in nevirapine rash. Clin Infect Dis 2001, 32(1):124-129.
• [7]Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, et al.: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005, 191(6):825-829.
• [8]Moore RD, Keruly JC, Chaisson RE: Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001, 15(5):617-620.
• [9]Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K: Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010, 153(6):349-357.
• [10]Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, et al.: Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357(9256):592-598.
• [11]Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, Rieger A, Wagner OF, Quehenberger P: Sex differences in HAART-associated dyslipidaemia. AIDS 2001, 15(6):725-734.
• [12]Umeh OC, Currier JS: Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2006, 2(2):273-283.
• [13]Floridia M, Giuliano M, Palmisano L, Vella S: Gender differences in the treatment of HIV infection. Pharmacol Res 2008, 58(3–4):173-182.
• [14]d’arminio Monforte A, Cozzi-Lepri A, Phillips A, de Luca A, Murri R, Mussini C, Grossi P, Galli A, Zauli T, Montroni M, et al.: Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian cohort of antiretroviral-naive patients. J Acquir Immune Defic Syndr 2005, 38(4):407-416.
• [15]Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kamya M, Achan J, Charlebois ED, Feeney ME: Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis 2011, 53(6):592-599.
• [16]Foca M, Moye J, Chu C, Matthews Y, Rich K, Handelsman E, Luzuriaga K, Paul M, Diaz C: Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV. Pediatrics 2006, 118(1):146-155.
• [17]Renner L, Prin M, Li FY, Goka B, Northrup V, Paintsil E: Time to and predictors of CD4+ T-lymphocytes recovery in HIV-infected children initiating highly active antiretroviral therapy in Ghana. AIDS Res Treat 2011, 2011:896040.
• [18]Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V: Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J 2009, 28(6):488-492.
• [19]Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, Bulterys M: Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006, 41(4):453-460.
• [20]Sztam KA, Jiang H, Jurgrau A, Deckelbaum RJ, Foca MD: Early increases in concentrations of total, LDL, and HDL cholesterol in HIV-infected children following new exposure to antiretroviral therapy. J Pediatr Gastroenterol Nutr 2011, 52(4):495-498.
• [21]Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, Levy-Marchal C: Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000, 14(14):2123-2128.
• [22]Arpadi S, Shiau S, Strehlau R, Martens L, Patel F, Coovadia A, Abrams EJ, Kuhn L: Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child 2013, 98(4):258-264.
• [23]Strehlau R, Coovadia A, Abrams EJ, Martens L, Arpadi S, Meyers T, Kuhn L: Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr 2012, 60(4):369-376.
• [24]Reitz C, Coovadia A, Ko S, Meyers T, Strehlau R, Sherman G, Kuhn L, Abrams EJ: Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis 2010, 201(8):1121-1131.
• [25]Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, et al.: Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis 2012, 12(7):521-530.
• [26]Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C: Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005, 115(4):e500.
• [27]Child growth standards and WHO Anthro and Macros [http://www.who.int/childgrowth/en/ webcite]
• [28]Horlick M, Arpadi SM, Bethel J, Wang J, Moye J, Cuff P, Pierson RN, Kotler D: Bioelectrical impedance analysis models for prediction of total body water and fat-free mass in healthy and HIV-infected children and adolescents. Am J Clin Nutr 2002, 76(5):991.
• [29]Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, Chi BH, Cotton MF, Moultrie H, Khadse S, et al.: Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012, 366(25):2380-2389.
• [30]Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, Dabis F, Wood R, Sprinz E, Schechter M, et al.: Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008, 22(17):2291-2302.
• [31]European Collaborative Study: Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr 2003, 33(5):635-641.
• [32]Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, Djedje M, Farquhar C: Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007, 44(4):371-376.
• [33]Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS: Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials 2007, 8(6):371-380.
• [34]Thiebaut R, Dequae-Merchadou L, Ekouevi DK, Mercie P, Malvy D, Neau D, Dabis F: Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996–99. HIV Med 2001, 2(2):84-88.
• [35]Currier JS, Martorell C, Osiyemi O, Yin MT, Ryan R, de la Rosa G, Mrus J: Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS 2011, 25(6):333-340.
• [36]Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA: A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006, 7(2):85-98.
• [37]Srinivasan SR, Wattigney W, Webber LS, Berenson GS: Race and gender differences in serum lipoproteins of children, adolescents, and young adults–emergence of an adverse lipoprotein pattern in white males: the Bogalusa heart study. Prev Med 1991, 20(6):671-684.
• [38]The Lipid Research Clinics Population Studies Data Book. Vol 1 In National Institutes of Health; Lipid Metabolism Branch; Division of Heart and Vascular Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute; 1980.
• [39]Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003, 42(2):81-92.
• [40]Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV: Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol 2011, 51(12):1665-1673.
• [41]Shiau S, Arpadi S, Strehlau R, Martens L, Patel F, Coovadia A, Abrams EJ, Kuhn L: Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr 2013. [Epub ahead of print]
• [42]Rosso R, Vignolo M, Parodi A, di Biagio A, Sormani MP, Bassetti M, Aicardi G, Bassetti D: Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy. AIDS Res Hum Retroviruses 2005, 21(11):927-932.
• [43]Taylor RW, Gold E, Manning P, Goulding A: Gender differences in body fat content are present well before puberty. Int J Obes Relat Metab Disord 1997, 21(11):1082-1084.
• [44]He Q, Horlick M, Thornton J, Wang J, Pierson RN Jr, Heshka S, Gallagher D: Sex and race differences in fat distribution among Asian, African-American, and Caucasian prepubertal children. J Clin Endocrinol Metab 2002, 87(5):2164-2170.
• [45]Staiano AE, Katzmarzyk PT: Ethnic and sex differences in body fat and visceral and subcutaneous adiposity in children and adolescents. Int J Obes (Lond) 2012, 36(10):1261-1269.
• [46]Spoulou V, Kanaka-Gantenbein C, Bathrellou I, Mora S, Mostrou G, Sidossis L, Chrousos G, Theodoridou M: Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy. Hormones (Athens) 2011, 10(2):149-155.
• [47]Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N, Houang M, Chevenne D, Hankard R, Bresson JL, et al.: Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005, 40(2):161-168.
• [48]Kinabo GD, Sprengers M, Msuya LJ, Shayo AM, van Asten H, Dolmans WM, van der Ven AJ, Warris A: Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. Pediatr Infect Dis J 2013, 32(1):39-44.
• [49]South Africa Department of Health. National antiretroviral treatment guidelines (first edition, 2004): section 2, antiretroviral treatment in children. [http://southafrica.usembassy.gov/media/2004-doh-art-guidelines.pdf webcite]